1. Scrip
  2. >>Conferences

NASH Updates: Boston Pharma, Viking Line Up As Serious Competitors

New Data Coming Out Of AASLD

 
• By Joseph Haas

Boston Pharma may be rising in the FGF21 space, while Viking could be formidable competition for Madrigal in the THRβ agonist class. Akero will soon report potentially groundbreaking data in cirrhotic NASH.

2023 AASLD
Boston Pharma, Viking and Akero raised their profiles in NASH at AASLD 2024 • Source: Scrip

In the non-alcoholic steatohepatitis (NASH) space, Novo Nordisk was the star of the 2024 American Association for the Study of Liver Disease meeting with additional data from its Phase III study of semaglutide in NASH, but Boston Pharmaceuticals and Viking Therapeutics appear to have gained momentum in the R&D race while the field is also looking ahead to expected data in February for Akero’s candidate in cirrhotic NASH patients.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Conferences

Stock Watch: Disappointing ACC Share Price Reactions For AstraZeneca And Lilly

 
• By Andy Smith

The end of the American College of Cardiology conference was a prelude to a volatile trading week for most stocks. Even before Liberation Day, reactions to the conference announcements were not encouraging.

AstraZeneca Oral PCSK9 Prospects Pumped After Phase IIb Win

 
• By Kevin Grogan

The UK giant is forecasting peak sales of $5bn plus

Balance And Focus Suggested For Globalizing Chinese Firms Amid Ongoing Uncertainties

 
• By Xu Hu

Finding a balance between out-licensing, refocusing on internal strengths and addressing unmet needs were identified at a recent Shanghai conference as some of the key strategies for Chinese biopharma firms looking to truly globalize.

Cash-Strapped Chinese Biotechs A Growing Draw For Western Pharma Partnering

 
• By Alaric DeArment

Nauman Shah, head of business development for J&J Innovation, sat down at the BIO CEO & Investor Conference to talk about his trip to China and the state of the biotech scene there.

More from Therapy Areas

Genentech To Try Repertoire’s Immune Synapse Technology In Autoimmune Disease

 
• By Joseph Haas

Deal snapshot: The Flagship portfolio firm will use its Decode platform to seek novel targets for an unspecified autoimmune disease, with Genentech holding license rights.

Sebela’s Tegoprazan Poised For GERD Market

 
• By Jessica Merrill

Two Phase III trials testing tegoprazan read out positively, but the potassium-competitive acid blocker will compete with Phathom’s Voquezna (vonoprazan).

In Brief: DIOSynVax And ACM Biolabs To Develop Bird Flu Vaccine

 
• By Sushmita Panda

The collaboration, supported by UK and Singapore government agencies, aims to develop an mRNA-based, needle-free universal bird flu vaccine suitable for use in a pandemic.